Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, England–(BUSINESS WIRE)–Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announced that it has…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara, Inc., a clinical-stage biopharmaceutical company focused on sickle cell disease and other hemoglobinopathies, today announced that the…
LEHI, Utah–(BUSINESS WIRE)–Frelii Inc. (OTCQB: FRLI) (“Frelii” or “the Company”) today announced it has issued a press release with the…
EUSA Pharma’s studies of Qarziba in treatment of high-risk neuroblastoma support the use of dinutuximab beta as standard-of-care immunotherapy for high-risk neuroblastoma patients.
LONDON–(BUSINESS WIRE)–Citi, acting through Citibank N.A., has been appointed by Bicycle Therapeutics plc, a biotechnology company pioneering a new class…
Obesity is a complex disease and leading cause of morbidity and mortality and there are only insufficient treatment options available…
Allergan and Gedeon Richter got the U.S. Food and Drug Administration approval for a supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine) for expanded use to treat depressive episodes associated with bipolar I disorder (bipolar depression) in adults.
Ansun Biopharma has welcomed the first patient to its Phase 3 clinical trial to test DAS181 a recombinant sialidase protein that can cleave sialic acid, the virus receptors located on the surface of epithelial cells lining the human respiratory track.
Schreiner MediPharm developed the Patch-Safe specialty label for PS Marketing & Outsourcing GmbH, to be used for safe disposal of patches containing active ingredients.
Preclinical study supports Vor’s approach for empowering targeted
immunotherapies through hematopoietic stem cell editing
Paper co-authored by Vor co-founder Dr. Siddhartha Mukherjee